Nymox Rated ''Bullish'' by Standard & Poor's Stock Reports; Nymox -NASDAQ: NYMX- also Receives $9.00 Price Target in New ''Buy'' Recommendation from CGF Securities.

MAYWOOD, N.J. -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) has received positive coverage in a new Standard & Poor's Stock Report. The new report on Nymox rates the stock as "bullish" on technical evaluation. The Stock Report was written by S&P analyst Craig C. Pratesi. The two page report analyzes the company's business activities and stock performance.

Nymox also received a new "Buy" recommendation in a New Update Report (July 2, 2004) from CGF Securities. CGF Securities Healthcare Analyst Clifford P. Murray, M.D. wrote the report which is available at www.cgfsecurities.com. According to Dr. Murray's revised report, he has a price target of $9.00 for Nymox.

More information about Nymox is available at www.nymox.com, email: [e-mail], or 1-800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in NYMOX's filings with the United States Securities and Exchange Commission and other regulatory authorities. CGF Securities, LLC, a subsidiary of Capital Growth Financial, Ltd. (the "Firm") currently makes a market in these securities. The Firm, its officers, directors, analysts or employees may effect transactions in and have long or short positions in the securities mentioned herein.